Apellis Pharmaceuticals, Inc. (APLS) Tops Q4 EPS by 85c

Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) reported Q4 EPS of $0.47, $0.85 better than the analyst estimate of ($0.38). Revenue for the quarter came in at $199.91 million versus the consensus estimate of $198.82 million.

For earnings history and earnings-related data on Apellis Pharmaceuticals, Inc. (APLS) click here.

You May Also Be Interested In

• Eli Lilly: Q2 2026 IPR&D charge estimated at $3.02 per share on GAAP and non-GAAP basis
• Thunder Mountain Gold plans $6.4M private placement for South Mountain
• Dollar Tree upgraded on earnings upside potential despite ongoing traffic woes